Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Fuller

Showing results (271-280 of 284) with videos related to

Pageof 29
Sort By:
International Journal of Radiation Oncology, Biology, Physics|September 9, 2020
Tumor Control Probability Modeling and Systematic Review of the Literature of Stereotactic Body Radiation Therapy for Prostate CancerTrevor J Royce, Panayiotis Mavroidis, Kyle Wang, et al.
Plos Neglected Tropical Diseases|February 24, 2023
Contextual determinants of mass drug administration performance: Modelling fourteen years of lymphatic filariasis treatments in West AfricaBrian B Fuller, Vance Harris, Caleb Parker, et al.
Nature Communications|November 18, 2024
A modular platform for bioluminescent RNA trackingLila P Halbers, Kyle H Cole, Kevin K Ng, et al.
The American Journal of Tropical Medicine and Hygiene|October 20, 2021
Restarting Neglected Tropical Diseases Programs in West Africa during the COVID-19 Pandemic: Lessons Learned and Best PracticesAchille Kabore, Stephanie L Palmer, Ernest Mensah, et al.
International Journal of Radiation Oncology, Biology, Physics|January 25, 2021
Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated PatientsRitchell van Dams, Naomi Y Jiang, Donald B Fuller, et al.
European Urology Oncology|April 12, 2026
Extended Follow-up from the Stereotactic Body Radiotherapy for High-risk Localized Carcinoma of the Prostate (SHARP) Consortium: Updated Analysis of 440 PatientsLuca F Valle, Tahmineh Romero-Kalbasi, Tommy Jiang, et al.
Advances in Radiation Oncology|September 29, 2021
Toxicity After Stereotactic Body Radiation Therapy for Prostate Cancer in Patients With Inflammatory Bowel Disease: A Multi-institutional Matched Case-Control SeriesJesus E Juarez, Tahmineh Romero, Constantine A Mantz, et al.
JAMA Network Open|February 9, 2019
Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate CancerAmar U Kishan, Audrey Dang, Alan J Katz, et al.
Cancer Treatment Reviews|May 9, 2021
Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensusBarbara A Jereczek-Fossa, Giulia Marvaso, Mattia Zaffaroni, et al.
BMJ Global Health|May 4, 2023
How well do coverage surveys and programmatically reported mass drug administration coverage match? Results from 214 mass drug administration campaigns in 15 countries, 2008-2017Kathryn L Zoerhoff, Pamela S Mbabazi, Katherine Gass, et al.
Pageof 29

Showing results (271-280 of 284) with videos related to

Sort By:
Pageof 29
International Journal of Radiation Oncology, Biology, Physics|September 9, 2020
Tumor Control Probability Modeling and Systematic Review of the Literature of Stereotactic Body Radiation Therapy for Prostate CancerTrevor J Royce, Panayiotis Mavroidis, Kyle Wang, et al.
Plos Neglected Tropical Diseases|February 24, 2023
Contextual determinants of mass drug administration performance: Modelling fourteen years of lymphatic filariasis treatments in West AfricaBrian B Fuller, Vance Harris, Caleb Parker, et al.
Nature Communications|November 18, 2024
A modular platform for bioluminescent RNA trackingLila P Halbers, Kyle H Cole, Kevin K Ng, et al.
The American Journal of Tropical Medicine and Hygiene|October 20, 2021
Restarting Neglected Tropical Diseases Programs in West Africa during the COVID-19 Pandemic: Lessons Learned and Best PracticesAchille Kabore, Stephanie L Palmer, Ernest Mensah, et al.
International Journal of Radiation Oncology, Biology, Physics|January 25, 2021
Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated PatientsRitchell van Dams, Naomi Y Jiang, Donald B Fuller, et al.
European Urology Oncology|April 12, 2026
Extended Follow-up from the Stereotactic Body Radiotherapy for High-risk Localized Carcinoma of the Prostate (SHARP) Consortium: Updated Analysis of 440 PatientsLuca F Valle, Tahmineh Romero-Kalbasi, Tommy Jiang, et al.
Advances in Radiation Oncology|September 29, 2021
Toxicity After Stereotactic Body Radiation Therapy for Prostate Cancer in Patients With Inflammatory Bowel Disease: A Multi-institutional Matched Case-Control SeriesJesus E Juarez, Tahmineh Romero, Constantine A Mantz, et al.
JAMA Network Open|February 9, 2019
Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate CancerAmar U Kishan, Audrey Dang, Alan J Katz, et al.
Cancer Treatment Reviews|May 9, 2021
Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensusBarbara A Jereczek-Fossa, Giulia Marvaso, Mattia Zaffaroni, et al.
BMJ Global Health|May 4, 2023
How well do coverage surveys and programmatically reported mass drug administration coverage match? Results from 214 mass drug administration campaigns in 15 countries, 2008-2017Kathryn L Zoerhoff, Pamela S Mbabazi, Katherine Gass, et al.
Pageof 29